NFE2L2 and acute kidney injury: Furthermore, alisol B targeted sEH to alleviate Cis-induced AKI via GSK3β-mediated p53, NF-κB, and Nrf2 signaling pathways, which was supported by the sEH genetic deletion experiment in vivo, suggesting that alisol B was a potential candidate to treat drug-induced AKI.